A phase 3 trial, SYNCHRONIZE-MASLD, has been conducted to study the effects of survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease. The trial results suggest that survodutide may have positive effects on weight loss, metabolic dysfunction, and fat reduction in the liver and visceral areas. However, there are also reports of tolerability concerns, with the overall outcome of the trial not entirely clear from the available information.